|
1
|
Biomarkers Definitions Working group.
Biomarkers and surrogate end points: preferred definitions and
conceptual framework. Clin Pharmacol Ther. 69:89–95. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Beastall GH, Cook B, Rustin GJS and
Jennings J: A review of the role of established tumor markers. Ann
Clin Biochem. 28:5–18. 1991. View Article : Google Scholar
|
|
3
|
Balch CM, Buzaid AC, Soong SJ, et al:
Final version of the American Joint Committee on Cancer staging
system for cutaneous melanoma. J Clin Oncol. 19:3635–3648.
2001.PubMed/NCBI
|
|
4
|
Gershenwald JE, Thompson W, Mansfield PF,
et al: Multi-institutional melanoma lymphatic mapping experience:
the prognostic value of sentinel lymph node status in 612 stage I
or II melanoma patients. J Clin Oncol. 17:976–983. 1999.
|
|
5
|
White RR, Stanley WE, Johnson JL, Tyler DS
and Seigler HF: Long-term survival in 2,505 patients with melanoma
with regional lymph node metastasis. Ann Surg. 235:879–887. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Barth A, Wanek LA and Morton DL:
Prognostic factors in 1,521 melanoma patients with distant
metastases. J Am Coll Surg. 181:193–201. 1995.PubMed/NCBI
|
|
7
|
Manola J, Atkins M, Ibrahim J, et al:
Prognostic factors in metastatic melanoma: a pooled analysis of
Eastern Cooperative Oncology Group trials. J Clin Oncol.
18:3782–3793. 2000.PubMed/NCBI
|
|
8
|
Bowen GM, Chang AE, Lowe L, et al:
Solitary melanoma confined to the dermal and/or subcutaneous
tissue: evidence for revisiting the staging classification. Arch
Dermatol. 136:1397–1399. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Karakousis CP, Velez A, Driscoll DL and
Takia H: Mastectomy in malignant melanoma. Surgery. 115:295–302.
1994.
|
|
10
|
Eton O, Legha SS, Moon TE, et al:
Prognostic factors for survival of patients treated systemically
for disseminated melanoma. J Clin Oncol. 16:1103–1111.
1998.PubMed/NCBI
|
|
11
|
Allen IE, Kupelnick B, Kumashiro M, et al:
Efficacy of interleukin-2 in the treatment of metastatic melanoma:
systematic review and meta-analysis. Cancer Ther. 1:168–173.
1998.
|
|
12
|
Bedikian AY, Johnson MM, Warneke CL, et
al: Prognostic factors that determine the long-term survival of
patients with unresectable metastatic melanoma. Cancer Invest.
26:624–633. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Balch CM, Wilkerson JA, Murad TM, et al:
The prognostic significance of ulceration of cutaneous melanoma.
Cancer. 45:3012–3017. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McGovern VJ, Shaw HM, Milton GW, et al:
Ulceration and prognosis in cutaneous malignant melanoma.
Histopathology. 6:399–407. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Balch CM, Soong SJ, Gershenwald JE, et al:
Prognostic factor analysis of 17,600 melanoma patients: validation
of the American Joint Committee on Cancer melanoma staging system.
J Clin Oncol. 19:3622–3634. 2001.PubMed/NCBI
|
|
16
|
Buzaid AC, Ross MI, Balch CM, et al:
Critical analysis of the current American Joint Committee on Cancer
staging system for cutaneous melanoma and proposal of a new staging
system. J Clin Oncol. 15:1039–1051. 1997.PubMed/NCBI
|
|
17
|
Cascinelli N, Belli F, Santinami M, et al:
Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma
Program experience. Ann Surg Oncol. 7:469–474. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Clemente CG, Mihm MC Jr, Bufalino R,
Zurrida S, Collini P and Cascinelli N: Prognostic value of tumor
infiltrating lymphocytes in vertical growth phase of primary
cutaneous melanoma. Cancer. 77:1303–1310. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mihm MC Jr, Clemente CG and Cascinelli N:
Tumor infiltrating lymphoctyes in lymph node mlelanoma metastases:
a histopathologic prognostic indicator and an expression of local
immune response. Lab Invest. 74:43–47. 1996.PubMed/NCBI
|
|
20
|
Healy E, Belgaid C, Takata M, et al:
Prognostic significance of allelic losses in primary melanoma.
Oncogene. 16:2213–2218. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brochez L and Naeyaert JM: Serological
markers for melanoma. Br J Dermatol. 143:256–268. 2000. View Article : Google Scholar
|
|
22
|
Sirott MN, Bajorin DF, Wong GY, et al:
Prognostic factors in patients with metastatic malignant melanoma:
a multivariate analysis. Cancer. 72:3091–3098. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Finck SJ, Giuliano AE and Morton DL: LDH
and melanoma. Cancer. 51:840–843. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
JaÈckel A, Deichman M, Waldmann V, et al:
S-100b protein in serum, a tumor marker in malignant melanoma
current state of knowledge and clinical experiences. Hautarzt.
50:250–256. 1999.PubMed/NCBI
|
|
25
|
Molina R, Navarro J, Filella X, Castel T
and Ballesta AM: S-100 protein serum levels in patients with benign
and malignant diseases: false-positive results related to liver and
renal function. Tumour Biol. 23:39–44. 2002. View Article : Google Scholar
|
|
26
|
Hauschild A, Michaelsen J, Brenner W, et
al: Prognostic significance of serum S100B detection compared with
routine blood parameters in advanced metastatic melanoma patients.
Melanoma Res. 9:155–161. 1999. View Article : Google Scholar
|
|
27
|
Hauschild A, Engel G, Brenner W, et al:
S100B protein detection in serum is a significant prognostic factor
in metastatic melanoma. Oncology. 56:338–344. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bonfrer JMG, Korse CM and Israels SP:
Serum S-100 has prognostic significance in malignant melanoma.
Anticancer Res. 17:2975–2978. 1997.PubMed/NCBI
|
|
29
|
Mocellin S, Zavagno G and Nitti D: The
prognostic value of serum S100B in patients with cutaneous
melanoma: a meta-analysis. Int J Cancer. 123:2370–2376. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Garbe C, Leiter U, Ellwanger U, et al:
Diagnostic value and prognostic significance of protein S-100beta,
melanoma-inhibitory activity and tyrosinase/MART-1 reverse
transcription-polymerase chain reaction in the follow-up of
high-risk melanoma patients. Cancer. 97:1737–1745. 2003. View Article : Google Scholar
|
|
31
|
Medic S, Pearce RL, Heenan PJ and Ziman M:
Molecular markers of circulating melanoma cells. Pigment Cell Res.
20:80–91. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kaskel P, Berking C, Sander S, et al:
S-100 protein in peripheral blood: a marker for melanoma
metastases. J Am Acad Dermatol. 41:962–969. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Von Schoultz E, Hansson LO, Djureen E, et
al: Prognostic value of serum analyses of S-100 beta protein in
malignant melanoma. Melanoma Res. 6:133–137. 1996.
|
|
34
|
Guo HB, Stoffel-Wagner B, Bierwirth T,
Mezger J and Klingmuller D: Clinical significance of serum S 100 in
metastatic malignant melanoma. Eur J Cancer. 31:1898–1902. 1995.
View Article : Google Scholar
|
|
35
|
Kärnell R, von Schoultz E, Hansson LO,
Nilsson B, Arstrand K and Kagedal B: S 100B protein,
5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid
as biochemical markers for survival prognosis in patients with
malignant melanoma. Melanoma Res. 7:393–399. 1997.PubMed/NCBI
|
|
36
|
Henze G, Dummer R, Joller-Jemelka HI, Boni
R and Burg G: Serum S 100-a marker for disease monitoring in
metastatic melanoma. Dermatology. 194:208–212. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Krähn G, Kaskel P, Sander S, et al: S 100
beta is a more reliable tumor marker in peripheral blood for
patients with newly occurred melanoma metastases compared with MIA,
albumin and lactate-dehydrogenase. Anticancer Res. 21:1311–1316.
2001.PubMed/NCBI
|
|
38
|
Hauschild A, Engel G, Brenner W, et al:
Predictive value of serum S 100B for monitoring patients with
metastatic melanoma during chemotherapy and/or immunotherapy. Br J
Dermatol. 140:1065–1071. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bosserhoff AK, Kaufmann M, Kaluza B, et
al: Melanoma inhibiting activity, a novel serum marker for
progression of malignant melanoma. Cancer Res. 57:3149–3153.
1997.PubMed/NCBI
|
|
40
|
Bosserhoff AK, Hein R, Bogdahn U, et al:
Structure and promoter analysis of the gene encoding the human
melanoma-inhibiting protein MIA. J Biol Chem. 271:490–495. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bosserhoff AK, Dreau D, Hein R, et al:
Melanoma inhibitory activity (MIA), a serological marker of
malignant melanoma. Recent Results. Cancer Res. 158:158–168.
2001.PubMed/NCBI
|
|
42
|
Dietz UH and Sandell LJ: Cloning of a
retinoic acid-sensitive mRNA expressed in cartilage and during
chondrogenesis. J Biol Chem. 271:3311–3316. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bosserhoff AK and Buettner R: Expression,
function and clinical relevance of MIA (melanoma inhibitory
activity). Histol Histopathol. 17:289–300. 2002.PubMed/NCBI
|
|
44
|
Bosserhoff AK, Moser M, Hein R, et al: In
situ expression patterns of melanoma-inhibiting activity (MIA) in
melanomas and breast cancers. J Pathol. 187:446–454. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Koehler MR, Bosserhoff A, von Beust G,
Bauer A, Blesch A, Buettner R, Schlegel J, Bogdahn U and Schmid M:
Assignment of the human melanoma inhibitory activity gene (MIA) to
19q13.4 by fluorescence in situ hybridization (FISH). Genomics.
35:264–267. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bosserhoff AK, Lederer M, Kaufmann M, et
al: MIA, a novel serum marker for progression of malignant
melanoma. Anticancer Res. 19:2691–2693. 1999.PubMed/NCBI
|
|
47
|
Kelley MC, Gupta RK, Hsueh EC, Yee R,
Stern S and Morton DL: Tumor associated antigen TA90 immune complex
assay predicts recurrence and survival after surgical treatment of
stage I–III melanoma. J Clin Oncol. 19:1176–1182. 2001.PubMed/NCBI
|
|
48
|
Faries MB, Gupta RK, Ye X, et al: A
comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III
melanoma patients. Cancer Invest. 25:285–293. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tsioulias G, Gupta RK, Tisman G, et al:
Serum TA90 antigen-antibody complex as a surrogate marker of the
efficacy of a polyvalent allogeneic whole-cell vaccine (Cancer-Vax)
in melanoma. Ann Surg Oncol. 8:198–203. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
DiFronzo L, Gupta RK, Essner R, et al:
Enhanced humoral immune response correlates with improved
disease-free and overall survival in American Joint Committee on
Cancer stage II melanoma patients receiving adjuvant polyvalent
vaccine. J Clin Oncol. 20:32422002.
|
|
51
|
Jones RC, Kelley MC, Gupta RK, et al:
Immune response to polyvalent melanoma cell vaccine in AJCC stage
III melanoma: an immunologic survival model. Ann Surg Oncol.
3:437–445. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chung M, Gupta RK, Hsueh E, et al: Humoral
immune response to a therapeutic polyvalent cancer vaccine after
complete resection of thick primary melanoma and sentinel
lymphadenectomy. J Clin Oncol. 21:313–319. 2003. View Article : Google Scholar
|
|
53
|
Kunter U, Buer J, Probst M, et al:
Peripheral blood tyrosinase messenger RNA detection and survival in
malignant melanoma. J Natl Cancer Inst. 88:590–594. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Smith B, Selby P, Southgate J, et al:
Detection of melanoma cells in peripheral blood by means of reverse
transcriptase and polymerase chain reaction. Lancet. 338:1227–1229.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Mellado B, Gutierrez L, Castel T, et al:
Prognostic significance of the detection of circulating malignant
cells by reverse transcriptase-polymerase chain reaction in
long-term clinically disease-free melanoma patients. Clin Cancer
Res. 5:1843–1848. 1999.
|
|
56
|
Mellado B, Colomer D, Castel T, et al:
Detection of circulating neoplastic cells by reverse-transcriptase
polymerase chain reaction in malignant melanoma: association with
clinical stage and prognosis. J Clin Oncol. 14:2091–2097. 1996.
|
|
57
|
Schittek B, Bodingbauer Y, Ellwanger U, et
al: Amplification of MelanA messenger RNA in addition to tyrosinase
increases sensitivity of melanoma cell detection in peripheral
blood and is associated with the clinical stage and prognosis of
melanoma. Br J Dermatol. 141:30–36. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Koyanagi K, Kuo C, Nakagawa T, Mori T,
Ueno H, Lorico AR Jr, Wang HJ, Hseuh E, O’Day SJ and Hoon DS:
Multimarker quantitative real-time PCR detection of circulating
melanoma cells in peripheral blood: relation to disease stage in
melanoma patients. Clin Chem. 51:981–988. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Matsuzaki Y, Hashimoto S, Fujita T, Suzuki
T, Sakurai T, Matsushima K and Kawakami Y: Systematic
identification of human melanoma antigens using serial analysis of
gene expression (sage). J Immunother. 28:10–19. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Reynolds SR, Albrecht J, Shapiro RL, Roses
DF, Harris MN, Conrad A, Zeleniuch-Jacquotte A and Bystryn JC:
Changes in the presence of multiple markers of circulating melanoma
cells correlate with clinical outcome in patients with melanoma.
Clin Cancer Res. 9:1497–1502. 2003.PubMed/NCBI
|
|
61
|
Schmidt H, Johansen JS, Gehl J, Geertsen
PF, Fode K and der Maase H: Elevated serum level of ykl-40 is an
independent prognostic factor for poor survival in patients with
metastatic melanoma. Cancer. 106:1130–1139. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Malinda KM, Ponce L, Kleinman HK,
Shackelton LM and Millis AJ: Gp38k, a protein synthesized by
vascular smooth muscle cells, stimulates directional migration of
human umbilical vein endothelial cells. Exp Cell Res. 250:168–173.
1999. View Article : Google Scholar
|
|
63
|
Schmidt H, Johansen JS, Sjoegren P, et al:
Serum YKL-40 predicts relapse-free and overall survival in patients
with American Joint Committee on Cancer stage I and II melanoma. J
Clin Oncol. 24:798–804. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Vergilis IJ, Szarek M, Ferrone S and
Reynolds SR: Presence and prognostic significance of
melanoma-associated antigens Cyt-Maa and Hmw-Maa in serum of
patients with melanoma. J Invest Dermatol. 125:526–531. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Reynolds SR, Vergilis IJ, Szarek M,
Ferrone S and Bystryn J: Cytoplasmic melanoma-associated antigen
(CYT-MAA) serum level in patients with melanoma: a potential marker
of response to immunotherapy? Int J Cancer. 119:157–161. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Brown JP, Hewick RM, Hellstrom I,
Hellstrom KE, Doolittle RF and Dreyer WJ: Human melanoma associated
antigen p97 is structurally and functionally related to
transferrin. Nature. 296:171–173. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Richardson DR: The role of the
membrane-bound tumour antigen, melanotransferrin (p97), in iron
uptake by the human malignant melanoma cell. Eur J Biochem.
267:1290–1298. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Brown JP, Nishiyama K, Hellstrom I and
Hellstrom KE: Structural characterization of human
melanoma-ssociated antigen p97 with monoclonal antibodies. J
Immunol. 127:539–546. 1981.PubMed/NCBI
|
|
69
|
Sekyere EO, Dunn LL and Richardson DR:
Examination of the distribution of the transferrin homologue,
melanotransferrin (tumour antigen p97), in mouse and human. Biochim
Biophys Acta. 1722:131–142. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Graeven U, Rodeck U, Karpinski S, Jost M,
Philippou S and Schmiegel W: Modulation of angiogenesis and
tumorigenicity of human melanocytic cells by vascular endothelial
growth factor and basic fibroblast growth factor. Cancer Res.
61:7282–7290. 2001.PubMed/NCBI
|
|
71
|
Sala R, Jefferies WA, Walker B, et al: The
human melanoma associated protein melanotransferrin promotes
endothelial cell migration and angiogenesis in vivo. Eur J Cell
Biol. 81:599–607. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Dunn LL, Sekyere EO, Suryo Rahmanto Y and
Richardson DR: The function of melanotransferrin: a role in
melanoma cell proliferation and tumorigenesis. Carcinogenesis.
27:2157–2169. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Levy C, Khaled M and Fisher DE: MITF:
master regulator of melanocyte development and melanoma oncogene.
Trends Mol Med. 12:406–414. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Garraway LA, Widlund HR, Rubin MA, et al:
Integrative genomic analyses identify MITF as a lineage survival
oncogene amplified in malignant melanoma. Nature. 436:117–122.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Koyanagi K, O’Day SJ, Gonzalez R, et al:
Microphthalmia transcription factor as a molecular marker for
circulating tumor cell detection in blood of melanoma patients.
Clin Cancer Res. 12:1137–1143. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Hoek KS, Schlegel NC, Bradfford P, et al:
Metastatic potential of melanomas defined by specific gene
expression profiles with no B-RAF signature. Pigment Cell Res.
19:290–302. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Maresh GA, Marken JS, Neubauer M, et al:
Cloning and expression of the gene for the melanoma-associated ME20
antigen. DNA Cell Biol. 13:87–95. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Scheibenbogen C, Weyers I, Ruiter D, et
al: Expression of gp100 in melanoma metastases resected before or
after treatment with IFN alpha and IL-2. J Immunother Emphasis
Tumor Immunol. 19:375–380. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Schrader AJ, Probst-Kepper M, Grosse J,
Kunter U, Schenk F, Franzke A, Atzpodien J and Buer J: Molecular
and prognostic classification of advanced melanoma: a multi-marker
microcontamination assay of peripheral blood stem cells. Melanoma
Res. 10:355–362. 2000. View Article : Google Scholar
|
|
80
|
Mahmoud FA and Rivera NI: The role of
C-reactive protein as a prognostic indicator in advanced cancer.
Curr Oncol Rep. 4:250–255. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Castell JV, Gómez-Lechón MJ, David M,
Andus T, Geiger T, Trullenque R, Fabra R and Heinrich PC:
Interleukin-6 is the major regulator of acute phase protein
synthesis in adult human hepatocytes. FEBS Lett. 242:237–239. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Deichmann M, Kahle B, Moser K, Wacker J
and Wu K: Diagnosing melanoma patients entering American Joint
Committee on Cancer stage IV, C-reactive protein in serum is
superior to lactate dehydrogenase. Br J Cancer. 91:699–702.
2004.
|
|
83
|
Mouawad R, Benhammouda A, Antoine EC,
Borel C, Weil M, Khayat D and Soubrane C: Endogenous interleukin 6
levels in patients with metastatic malignant melanoma: correlation
with tumor burden. Clin Cancer Res. 2:1405–1409. 1996.PubMed/NCBI
|
|
84
|
Tartour E, Dorval T, Mosseri V, Deneux L,
Mathiot C, Brailly H, Montero F, Joyeux I, Pouillart P and Fridman
WH: Serum interleukin 6 and C-reactive protein levels correlate
with resistance to IL-2 therapy and poor survival in melanoma
patients. Br J Cancer. 69:911–913. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Deichmann M, Benner A, Jackel A, Bock M,
Waldmann V and Naher H: Elevated interleukin-6 serum levels
indicate progressive disease in metastasized malignant melanoma. J
Exp Clin Cancer Res. 19:301–307. 2000.
|
|
86
|
Tartour E, Blay JY, Dorval T, Escudier B,
Mosseri V and Douillard JY: Predictors of clinical response to
interleukin-2-based immunotherapy in melanoma patients: a French
multiinstitutional study. J Clin Oncol. 14:1697–1703.
1996.PubMed/NCBI
|
|
87
|
Jacob K, Sollier C and Jabado N:
Circulating tumor cells: detection, molecular profiling and future
prospects. Expert Rev Proteonomics. 4:741–756. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Mocellini S, Del Fiore P, Guarnieri L, et
al: Molecular detection of circulating tumor cells is an
independent prognostic factor in patients with high-risk cutaneous
melanoma. Int J Cancer. 111:741–745. 2004. View Article : Google Scholar
|
|
89
|
Ulmer A, Schmidt-Kittler O, Fischer J,
Ellwanger U, Rassner G, Riethmüller G, Fierlbeck G and Klein CA:
Immunomagnetic enrichment, genomic characterization and prognostic
impact of circulating melanoma cells. Clin Cancer Res. 10:531–537.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Keilholz U, Martus P, Punt CJ, et al:
Prognostic factors for survival and factors associated with
long-term remission in patients with advanced melanoma receiving
cytokine-based treatments: Second analysis of a randomized EORTC
Melanoma Group trial comparing interferon-2a and interleukin-2
(IL-2) with or without cisplatin. Eur J Cancer. 38:1501–1511.
2002.
|
|
91
|
Linette GP, Carlson JA, Slominski A, Mihm
MC and Ross JS: Biomarkers in melanoma: stage III and IV disease.
Expert Rev Mol Design. 5:65–74. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Mellado B, Del Carmen V, Colomer D, et al:
Tyrosinase mRNA in blood of patients with melanoma treated with
adjuvant interferon. J Clin Oncol. 20:4032–4039. 2002. View Article : Google Scholar : PubMed/NCBI
|
